Gary Patou

CIK: 0001283535

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)3 (25.0%)

Position reduction

Option Exercises (M)3 (25.0%)

Derivative conversions

Awards (A)4 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)2 (16.7%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

XENE

Xenon Pharmaceuticals Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (12 total)

XENE
Xenon Pharmaceuticals Inc.
Jun 5, 2026
Sale(S)
Direct
1.3K shares at avg. $53.14$70K
XENE
Xenon Pharmaceuticals Inc.
Jun 3, 2026
Award(A)
Share Option (Right to Buy)
Direct
10.5K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 3, 2026
Award(A)
Restricted Share Units
Direct
1.6K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 1, 2026
Exercise(M)
Direct
2.6K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 5, 2025
Award(A)
Share Option (Right to Buy)
Direct
17K shares-
XENE
Xenon Pharmaceuticals Inc.
Jun 5, 2025
Award(A)
Restricted Share Units
Direct
2.6K shares-
XENE
Xenon Pharmaceuticals Inc.
Nov 22, 2024
Tax Payment(F)
Direct
1K shares at avg. $39.80$42K
XENE
Xenon Pharmaceuticals Inc.
Nov 22, 2024
Sale(S)
Direct
2K shares at avg. $41.05$84K
XENE
Xenon Pharmaceuticals Inc.
Nov 22, 2024
Tax Payment(F)
Direct
649 shares at avg. $39.80$26K
XENE
Xenon Pharmaceuticals Inc.
Nov 22, 2024
Sale(S)
Direct
2.9K shares at avg. $41.11$117K
XENE
Xenon Pharmaceuticals Inc.
Nov 22, 2024
Exercise(M)
Direct
3.5K shares at avg. $7.38$26K
XENE
Xenon Pharmaceuticals Inc.
Nov 22, 2024
Exercise(M)
Direct
3.1K shares at avg. $13.48$42K

		Type	Shares	Price		Ownership
Jun 5, 2026	XENE Xenon Pharmaceuticals Inc.	Sale(S)	1,322	$53.14	$70,251	Direct
Jun 3, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	10,507	-	-	Direct
Jun 3, 2026	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	1,593	-	-	Direct
Jun 1, 2026	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	2,645	-	$0	Direct
Jun 5, 2025	XENE Xenon Pharmaceuticals Inc.	Award(A) Share Option (Right to Buy)	17,012	-	-	Direct
Jun 5, 2025	XENE Xenon Pharmaceuticals Inc.	Award(A) Restricted Share Units	2,645	-	-	Direct
Nov 22, 2024	XENE Xenon Pharmaceuticals Inc.	Tax Payment(F)	1,046	$39.80	$41,631	Direct
Nov 22, 2024	XENE Xenon Pharmaceuticals Inc.	Sale(S)	2,040	$41.05	$83,742	Direct
Nov 22, 2024	XENE Xenon Pharmaceuticals Inc.	Tax Payment(F)	649	$39.80	$25,830	Direct
Nov 22, 2024	XENE Xenon Pharmaceuticals Inc.	Sale(S)	2,851	$41.11	$117,205	Direct
Nov 22, 2024	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	3,500	$7.38	$25,830	Direct
Nov 22, 2024	XENE Xenon Pharmaceuticals Inc.	Exercise(M)	3,086	$13.48	$41,599	Direct

1-12 of 12 transactions

About PATOU GARY

PATOU GARY (SEC CIK 0001283535) files insider reports with the SEC as Director of Xenon Pharmaceuticals Inc. (XENE).

Signal8 holds 4 ownership filings by PATOU GARY, all Form 4s, filed between Nov 22, 2024 and Jun 8, 2026. Those filings report 12 transactions, from Nov 22, 2024 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on PATOU GARY's filings is in BURNABY.

Recent filings by PATOU GARY

Jun 5, 2026: Open-market sale of XENE shares (Form 4, code S).
Jun 3, 2026: Grants or awards of XENE derivative securities (2 lines, Form 4, code A).
Jun 1, 2026: Option exercise of XENE shares (Form 4, code M).
Jun 5, 2025: Grants or awards of XENE derivative securities (2 lines, Form 4, code A).
Nov 22, 2024: Tax withholding of XENE shares (Form 4, code F).

Other insiders filing for Xenon Pharmaceuticals Inc. (XENE)

Kelly Thomas Patrick, Chief Financial Officer
MORTIMER IAN, PRESIDENT & CEO
Svoronos Dawn, Director
GANNON STEVEN, Director
Cannon Gillian, Director
Machado Patrick, Director

How to read Form 4 transaction codes